Northpointe Capital LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel reports. The fund acquired 34,261 shares of the biopharmaceutical company’s stock, valued at approximately $2,454,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. SeaBridge Investment Advisors LLC grew its stake in shares of Gilead Sciences by 56.0% during the fourth quarter. SeaBridge Investment Advisors LLC now owns 30,063 shares of the biopharmaceutical company’s stock valued at $2,154,000 after buying an additional 10,793 shares during the last quarter. WoodTrust Financial Corp bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $512,000. Comprehensive Portfolio Management LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $892,000. Hudson Capital Management LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $1,018,000. Finally, Webster Bank N. A. grew its stake in shares of Gilead Sciences by 108.7% during the fourth quarter. Webster Bank N. A. now owns 2,928 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 1,525 shares during the last quarter. 75.71% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, EVP Gregg H. Alton sold 14,435 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 432,768 shares of company stock valued at $33,919,138. 1.30% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.70 earnings per share. equities analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is currently 59.77%.
GILD has been the topic of a number of analyst reports. Mizuho upped their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Maxim Group set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, December 7th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a research note on Wednesday, January 17th. Finally, Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $81.19 to $93.00 in a research note on Friday, January 26th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $86.92.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3225104/northpointe-capital-llc-acquires-shares-of-34261-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.